Abstract Amyloid imaging has identified cognitively normal older people with plaques as a group possibly at increased risk for developing Alzheimer's disease-related dementia. It is important to begin to thoroughly characterize this group so that preventative therapies might be tested. Existing cholinotropic agents are a logical choice for preventative therapy as experimental evidence suggests that they are anti-amyloidogenic and clinical trials have shown that they delay progression of mild cognitive impairment to dementia. A detailed understanding of the status of the cortical cholinergic system in preclinical AD is still lacking, however. For more than 30 years, depletion of the cortical cholinergic system has been known to be one of the characteristic features of AD. Reports to date have suggested that some cholinergic markers are altered prior to cognitive impairment while others may show changes only at later stages of dementia. These studies have generally been limited by relatively small sample sizes, long postmortem intervals and insufficient definition of control and AD subjects by the defining histopathology. We, therefore, examined pre-and post-synaptic elements of the cortical cholinergic system in frontal and parietal cortex in 87 deceased subjects, including non-demented elderly with and without amyloid plaques as well as demented persons with neuropathologically confirmed AD. Choline acetyltransferase (ChAT) activity was used as a presynaptic marker while displacement of 3 H-pirenzepine binding by oxotremorine-M in the presence and absence of GppNHp was used to assess postsynaptic M1 receptor coupling. The results indicate that cortical ChAT activity as well as M1 receptor coupling are both significantly decreased in nondemented elderly subjects with amyloid plaques and are more pronounced in subjects with AD and dementia. These findings confirm that cortical cholinergic dysfunction in AD begins at the preclinical stage of disease and suggest that cholinotropic agents currently used for AD treatment are a logical choice for preventative therapy.
Introduction
In the early years of the last century, Alzheimer's disease was defined by the presence of microscopic lesions known as senile (amyloid) plaques and neurofibrillary tangles. Pioneering biochemical investigations in the 1970s identified that AD subjects had significant losses of basal forebrain cholinergic neurons along with their cortically projecting axons, leading to cholinergic replacement therapy, which remains the major treatment option. There has been a long-standing controversy, however, over where cholinergic degeneration occurs within the pathogenic sequence leading to AD. That cholinergic depletion is a primary pathogenic event was supported by multiple early studies showing that depletion of choline acetyltransferase (ChAT), the enzyme that converts choline to acetylcholine in presynaptic nerve terminals, could be detected soon after the onset of cognitive dysfunction, in some studies utilizing cerebral cortex biopsies [12, 66, 68] . The findings that several other neurotransmitters were also depleted in AD cortex, and the failure of cholinergic therapy to reverse the disease course, changed this conception. The primary change in AD came to be accepted as death or dysfunction of cerebral cortex neurons due to local plaque and/or tangle burden while loss of basal forebrain cholinergic neurons and their cortically projecting axons was relegated to a secondary, retrograde status [67] . Subsequently, some research groups reported that decreases in cortical cholinergic presynaptic markers occurred only in the later clinical stages of AD [22, 23, 33, 38] , after the appearance of dementia. Other published studies indicated a more complex status, with some cortical and/or basal forebrain cholinergic markers being altered prior to the onset of mild cognitive impairment, whereas others showed changes only in later stages of dementia [3, 4, 14, 31, 32, 39, 57, 58, 83] . Recent imaging investigations of the cortical cholinergic system in living human subjects have generally supported an early situation of the deficit, at the stage of mild cognitive impairment or mild dementia [50, 60, 77] . Taken together, these findings suggest that the cortical cholinergic deficit begins at the preclinical stage of AD, which, as suggested by recent amyloid imaging results [53, 56, 73, 75] , may tentatively be defined as occurring in nondemented elderly individuals with cortical amyloid plaques.
Determining the stage of AD at which cholinergic deficits appear is not just an academic exercise. Events that occur near the beginning of disease pathogenesis are likely to be better therapeutic targets, as treatment at an earlier stage of disease will presumably prevent more of the downstream consequences of the disease process than treatment at a later stage. Despite an existing dogma that cholinergic agents do not modify the biological disease course, considerable evidence has accumulated to the contrary and has largely been ignored. In vitro studies have shown that M1 muscarinic receptor activation leads to changes in the cleavage pattern of the b-amyloid precursor protein (bAPP) that favor decreased production of Ab [16, 17, 21, 25, 27, 62] . This effect has been confirmed in vivo, in both animals [9, 48] and humans [2, 37, 61] . Conversely, decreased activation of M1 receptors leads to increased expression of bAPP and evidence of increased amyloidogenic cleavage or increased accumulation of Ab [5, 8, 21, 79] . In addition, there is now considerable clinical data, derived from both cognitive and imaging measures, to suggest that therapy with cholinergic agents delay disease progression, and are not merely palliative, as has long been assumed [11, 15, 40, 46, 49, 55, 72] . Most recently, a large authoritative trial by the Alzheimer's Disease Cooperative Study showed that some MCI subjects that were treated with donepezil, the major acetylcholinesterase inhibitor used for AD therapy, had a delayed conversion to dementia [49, 72] .
Although the loss of cortical cholinergic presynaptic terminal markers in AD is well established, the status of post-synaptic receptors is more complicated. Although there may be little or no change, or possibly a compensatory increase, in the number of cortical M1 receptors in AD [64, 65, 70, 84] , M1 receptor signal transduction-related markers or function are reportedly decreased or impaired in AD [26, 84, 85] . Muscarinic agonist stimulation of responses, such as binding of [ 35 S]GTPcS to G-proteins, GTPase activity, phosphoinositide hydrolysis and protein kinase C activity, are markedly decreased in AD [34, 59, 80, 81] . These studies indicate that the M1 receptor becomes uncoupled from its G-protein in Alzheimer's disease. Coupling of M1 receptors to G-proteins has not been quantitatively investigated in preclinical AD.
Previous studies of presynaptic and postsynaptic cholinergic markers in AD have been limited by relatively small sample sizes, long postmortem intervals and insufficient subdivision of controls and AD subjects by the defining histopathology. We therefore undertook a reassessment of the status of cortical cholinergic synaptic components utilizing a large number of neuropathologically characterized subjects from a rapid autopsy program.
Pre-and postsynaptic cholinergic status was examined in brains from 59 non-demented elderly controls with varying amounts of cortical amyloid plaques. Young and AD groups were included for comparison. ChAT activity was used as a presynaptic marker and was measured in frontal and parietal cortices. Displacement of 3 H-pirenzepine binding by oxotremorine-M in the presence and absence of GppNHp was measured in frontal cortex to assess the functional coupling of the postsynaptic M1 receptor with its G-protein (G q11 ).
Our results indicate that cortical ChAT activity is significantly decreased in non-demented elderly subjects with plaques, as compared to non-demented elderly subjects without plaques, with the severity of ChAT activity loss being proportionate to the plaque density. Coupling of M1 receptors to G-proteins is also impaired in non-demented controls with plaques compared to that in non-demented controls without plaques. These findings suggest that cortical cholinergic degeneration and dysfunction in AD begins at the preclinical stages of disease, before the onset of dementia, in parallel with the accumulation of cortical amyloid plaques.
Materials and methods

Human subjects
The study took place at Banner Sun Health Research Institute (BSHRI), located in the Sun Cities retirement communities of northwest metropolitan Phoenix, Arizona. The Institute is part of Banner Health, a regional not-forprofit health care provider centered in Arizona. Brain necropsies were performed on elderly subjects who had volunteered for the BSHRI Brain Donation Program, a longitudinal clinicopathologic study of normal aging, dementia and parkinsonism [7] . The operations of the Brain Donation Program have been approved by the Institutional Review Board of Banner Health. Subjects were chosen by searching the Brain Donation Program database. A young control group was derived from a hospital autopsy series. Non-demented control subjects were defined as those that had not had a clinical diagnosis of dementia or parkinsonism. Subjects with AD were defined as those that had clinically documented dementia and a neuropathological diagnosis of AD. In addition, both AD and control subjects were chosen on the basis of availability of short postmortem interval (PMI \ 8 h) fresh-frozen cerebral cortex for biochemical analysis. Subjects were clinically characterized by standardized periodic neurological and neuropsychological assessments, review of medical records, self-report and telephone interviews with spouses and/or caregivers. A subset of subjects in this study received at least one Mini Mental State Examination (MMSE).
As part of the Brain Donation Program's standard protocol, 2 years of private medical records are obtained from the subjects' private physicians, both at the time of enrollment and at the time of death. Subjects also fill out a medical history questionnaire in which they are asked to report any significant neurological conditions. In addition, at the time of death, a telephone interview is conducted with the spouse and/or caregiver in which the presence of any neurological conditions, symptoms or signs are again queried.
For the purpose of this study, the subjects were divided into groups on the basis of age, presence or absence of dementia and senile plaque density. The elderly nondemented controls were divided into three subgroups: those without plaques (no plaques, NPL), those with plaque density scores in the lower 50% of the plaque score range (sparse plaques, SPL) and those with plaque scores in the upper 50% of the range (many plaques, MPL) (see ''Materials and methods'' below for details of plaque scoring method). Two other groups were composed of young normal subjects and subjects who had dementia during life as well as a neuropathological diagnosis of Alzheimer's disease.
Tissue processing and histological methods
The cerebrum was cut in the coronal plane into 1-cm thick slices while the brainstem was sliced axially at 1-cm intervals. The entire brain was then divided sagittally into left and right halves. The slices from the right half were frozen between slabs of dry ice while the slices from the left half were fixed by immersion in buffered 4% formaldehyde for 48 h at 4°C. Following cryoprotection in ethylene glycol and glycerol, selected 3 9 4 cm cerebral, cerebellar and brainstem blocks were sectioned at 40-lm thickness on a sliding freezing microtome. The cerebral sections were taken at standard coronal levels as follows. For frontal lobe, the entire frontal cortical ribbon from cingulate gyrus to the middle frontal gyrus was assessed at the level of the genu of the corpus callosum. For temporal lobe, the entire neocortical ribbon was evaluated at the level of the amygdala, level of the pes hippocampus and level of the lateral geniculate nucleus. For parietal lobe, the entire parietal cortical ribbon from the cingulate gyrus to the inferior parietal lobule was assessed at a level 1-2 cm posterior to the trigone. For occipital lobe, the entire cortical ribbon, including primary and association cortical regions, was assessed at a level 2-3 cm anterior to the pole. Entorhinal cortex was assessed at the two anterior temporal lobe levels as described above. For hippocampus, the CA1 field was assessed at the two posterior temporal lobe levels as described above.
Additionally, a standard set of 24 brainstem, cerebellar and cerebral blocks were embedded in paraffin, cut at 6 lm and stained with hematoxylin and eosin. Freefloating 40 lm sections were stained with H & E, thioflavine S and enhanced silver methods for amyloid plaques and neurofibrillary tangles (Campbell-Switzer and Gallyas methods, respectively). Immunostaining for Ab was not performed. Amyloid plaques and neurofibrillary tangles were graded and staged based on the aggregate impression from 40-lm sections stained with thioflavine S, Campbell-Switzer and Gallyas methods. Scores for total plaque density (''plaque score'' in Table 2 ; Fig. 3 : neuritic and diffuse plaques considered together) and neurofibrillary tangle density (''tangle score'' in Table 2 ; Fig. 4 ) were obtained with reference to the CERAD templates [54] , assigning scores of zero, sparse, moderate and frequent to the standard regions within frontal cortex, temporal cortex, parietal cortex, hippocampus and entorhinal area as described above. Conversion of these to numerical values results in a score of 0-3 for each area, with a maximum score of 15 for all five areas combined. Neurofibrillary tangle abundance and distribution was also graded in these thick sections according to the original Braak protocol [13, 20] Table 2 ). Diagnostic criteria for AD were those established by CERAD and NIA-Reagan consortia [1, 54] . All subjects except the young controls were genotyped for apolipoprotein E (ApoE) using a modification of a standard method [36] .
Measurement of ChAT activity
ChAT was measured in frozen cortical tissue from frontal and parietal cortex using a standard method [28] . Tissues were stored at -80°C, then thawed and homogenized by sonication in 19 volumes of 75 mM potassium phosphate buffer, pH 7.4. Equal aliquots of homogenate and buffered substrate solution (75 mM potassium phosphate solution, pH 7.4, NaCl 0.6 mM, MgCl 2 40 mM, physostigmine 2 mM, bovine serum albumin 0.05%, choline iodide 10 mM, acetyl CoA, 0.87 mM, 3 H-acetyl CoA, 4.35 lCi) were incubated for 30 min at 37°C. Radiolabelled acetylcholine (ACh) was extracted by mixing with 150 ll of 3-heptanone: 75 mg/ml sodium tetraphenylboron. Organic and aqueous phases were separated by centrifugation and 3 H-ACh was determined in the organic phase by liquid scintillation spectrometry. Each sample was assayed in triplicate. Protein was measured by the method of Lowry. Data were expressed as pmoles acetylcholine (ACh) formed/mg protein/min.
Receptor concentration and binding assays
Preparation of P2 membranes was performed as described previously [82] . Tissues were homogenized in 10 volumes of ice-cold 0.32 M sucrose, containing 5 mM EDTA, 0.1 mM PMSF, and 0.02% azide. The sample was centrifuged at 1,000g for 10 min, the supernatant was decanted and kept on ice. The pellet was resuspended and recentrifuged. The combined supernatants were centrifuged at 15,000g for 20 min, and the resulting pellet resuspended in 50 mM potassium phosphate buffer containing 5 mM EDTA, 0.1 mM PMSF, and 0.02% NaN 3 . This was centrifuged at 15,000g for 20 min, resuspended and centrifuged again at 15,000g. The pellet was suspended in phosphate buffer (2.5 ml/g wet weight of the tissue).
For determination of M1 muscarinic receptor binding, the membranes were diluted 1:50 with 20 mM Tris buffer, pH 7.4, containing 1 MM MnCl 2 (protein concentration, 0.4 mg/ml), 3 H-pirenzepine (NEN, sp. act. 70 Ci/mmol) was added to a final concentration of 4 nM and oxotremorine-M was added in concentrations from 10 -12 to 3 9 10 -6 M. GppNHp (0.2 mM) was added to half of the samples. The samples were kept at room temperature for 1 h, then placed on ice and filtered through Whatman GF/C filters presoaked with 0.3% polyethenimine, and washed with ice-cold Tris in a Brandel cell harvester. The filters were dissolved overnight in scintillation fluid, then radioactivity determined by liquid scintillation spectroscopy. Specific binding is defined as total binding minus that in the presence of 1 lM atropine (non-specific binding). Binding curves were analyzed using GraphPad Prism software for one-site and two-site competition. The cases from the young control subject group were used only for ChAT activity determinations and not for receptor binding assays.
Statistical analyses
Statistical analyses for comparing group means consisted of one-way analysis of variance (ANOVA) followed by post-hoc pairwise significance testing. Corrections were made for multiple comparisons. Proportions were compared using v 2 tests. Correlations were done using Spearman's rank correlation method. Best fits for the displacement curves were obtained using non-linear regression for one-and two-site competition using Graph Pad Prism software. For all tests, the results were considered significant for p \ 0.05.
Results
Characteristics of study subjects
The basic characteristics of the study subjects are shown in Table 1 . The young control (YG) group differed significantly from all other groups with respect to age and postmortem interval. The groups differed in their percentages carrying the apoE-e4 allele, with the MPL and AD groups having significantly higher percentages (45 and 68%, respectively) than the NPL and SPL groups (11 and 18%, respectively). Table 2 shows mean plaque and tangle density scores for the groups; these differed as expected based on the group definitions. The NPL group differed significantly from the MPL and AD groups in terms of Braak neurofibrillary tangle stage. In terms of incidental neuropathological findings, Lewy bodies were present in eight of the AD subjects, five of the NPL group, five of the SPL group and one of the MPL group while cerebral infarcts were present in eight of the AD group (median infarct size 1 cm 3 ), eight of the NPL group (median 2.2 cm 3 ), seven of the SPL group (median 2 cm 3 ) and four of the MPL group (median 1 cm 3 ).
Cortical ChAT activity in the study groups Figures 1 and 2 show mean frontal and parietal ChAT activity in the study groups. There is a progressive decline in ChAT activity proceeding from YG through NPL, SPL, MPL and AD groups. In both frontal and parietal cortex, the groups were found to be significantly different (ANOVA, p \ 0.0001) and pairwise significance testing showed that the YG, NPL and SPL groups differed significantly from the MPL and AD groups. With the YG group values defined as 100%, ChAT activity declined sequentially in the NPL, SPL, MPL and AD groups to 96, 84, 71 and 57%, respectively. Figures 3 and 4 show correlations of ChAT activity with plaque and tangle density scores. Correlation coefficients were 0.48 and 0.57 for ChAT versus plaque score in frontal and parietal cortex, respectively. The correlations between ChAT and tangles were also significant, although the correlation coefficients were somewhat lower: 0.41 in frontal cortex and 0.42 in parietal cortex. Figure 5 shows correlations of ChAT activity with MMSE scores. These correlations were significant (p \ 0.01) in both frontal and parietal cortex, with correlation coefficients of 0.51 and 0.44, respectively.
ChAT activity did not differ when groups were divided by the presence or absence of the apolipoprotein E-e4 allele.
Receptor binding measures in the study groups
There was no significant difference in specific binding of 3 H-pirenzepine in the different groups, indicating that the number of M1 receptors does not differ between groups (data not shown). However, when displacement of the antagonist 3 H-pirenzepine by the agonist oxotremorine-M was examined, uncoupling of the M1 receptor from its G-protein complex was seen in all of the groups with plaques. Coupling of M1 muscarinic receptors can be demonstrated by assessing displacement curves of an antagonist by an agonist, in the presence and absence of the non-hydrolyzable GTP analog GppNHp. The addition of GppNHp shifts the displacement curve for antagonist by agonist to the right, indicating functional uncoupling of the M1 receptor/G-protein complex [74] . Figure 6 shows curves for displacement of 3 H-pirenzepine by oxotremorine-M in the three non-demented groups with varying plaque levels, and in the AD group. The curve was shifted significantly to the right by adding GppNHp in the nondemented control group with no plaques (NPL), indicating that the M1 receptor was coupled to the G-protein in this group. However, addition of GppNHp produced little change in the displacement curves in the non-demented samples with plaques (SPL, MPL) or in the AD group, indicating that the receptors had become uncoupled. The K i value was significantly different in the absence and presence of GppNHp in the non-demented control group without plaques, but there were no significant differences in the other groups. In addition, the proportion of M1 receptors in the high-affinity binding state was determined by examining two-site competition, and was found to be reduced in the non-demented control groups with plaques, compared with that without plaques (Fig. 7) . A reduction in high-affinity binding sites was also observed in the samples from AD subjects. These reductions correlated significantly with plaque score (Spearman's correlation, r = 0.36).
Discussion
The results of this investigation indicate that cortical ChAT activity is progressively decreased in non-demented elderly subjects in concert with the progressive accumulation of cortical amyloid plaques and this decrease is further accentuated in subjects with dementia associated with neuropathologically confirmed AD. This firmly places the presynaptic cholinergic deficit at a very early stage of AD. The association of a cortical cholinergic presynaptic deficit with amyloid plaques in non-demented subjects has been previously reported [3, 4, 43] ; the present study confirms these and also documents, for the first time, a postsynaptic cholinergic abnormality in non-demented subjects with plaques, consisting of uncoupling of cortical M1 receptors from their G-proteins as well as a reduction in high-affinity M1 binding sites. This work supports a growing agreement that several different markers of the cortical cholinergic system are affected early in the disease, at the stage of mild cognitive impairment or even prior to this [14, 50, 57, 58, 60, 77] . Recent amyloid imaging results [53, 56, 73, 75] have confirmed the longstanding neuropathological documentation of the frequent presence of cortical amyloid plaques in the non-demented elderly [10, 19, 20, 24] . It seems increasingly likely that non-demented subjects with cortical amyloid plaques represent a preclinical stage of AD. The results presented here strongly support this developing consensus, as our group of non-demented elderly subjects with plaques have plaques, tangles, a cholinergic deficit and an increased prevalence of the apoE-e4-allele. It might be expected that since the ascending cholinergic system has been thought to have a stimulatory effect on cerebral metabolism [42, 63] that the decreases in cortical cholinergic afferentation that are present in plaque-positive non-demented elderly should be accompanied by decreases in cerebral glucose metabolism, however, imaging studies to date have largely failed to find a correlation between measures of amyloid load and glucose metabolism in such subjects [18] . However, some evidence indicates that while the basal forebrain cholinergic system has great influence over cerebral blood flow, its effects on cerebral glucose metabolism may be comparatively small [47] .
Some studies of cortical cholinergic markers [22, 23, 33, 38] have been interpreted as evidence that the cortical cholinergic deficit is a late-stage event in AD. These studies, however, defined their study groups by clinical dementia staging rather than by histopathologic criteria, thereby including subjects in the dementia category that did not meet histopathologic diagnostic criteria for AD. Similarly, some subjects within the normal control categories had high densities of cortical neuritic plaques as well as Braak III or IV neurofibrillary tangle stages and would have met consensus clinicopathologic criteria for AD had they been demented. The resultant mixing of cases with and without histopathologic AD would have impaired the statistical power of these studies and increased the probability of false-negative results. In the present study, the diagnosis of AD was based on the clinical presence of dementia in association with neuropathological criteria for AD. Furthermore, non-demented elderly control subjects were subdivided on the basis of neocortical plaque densities into ''true'' controls (without plaques) and putative preclinical AD (with plaques).
It is known that astrocytes have M1 receptors and therefore may have influenced our measurements. We have not quantified the astrocytes in our subjects, but there is a well-documented astrocytic reaction in brain tissue affected by Alzheimer's disease histopathology, especially around neuritic plaques. Therefore, it is almost certain that our diagnostic groups would have an astrocyte reaction that was proportional to the density of neuritic plaques. As a literature search revealed no published data regarding activation-related changes in astrocytic M1 receptor numbers or characteristics, it is not possible to know if such changes exist and affected our study.
It is also possible that medications being taken in the perimortem period may have affected some or our measurements. Unfortunately, we do not have the details, for all of our subjects, of the medications being taken in the immediate postmortem period, but most elderly subjects have their AD-related medications withdrawn as they enter hospice care.
It is logical that, like other chronic diseases, AD has a prolonged preclinical period and that the disease does not begin only when it becomes symptomatic. We have considered that, since the cortical cholinergic deficit in non-demented aging humans begins when subjects are in their 50s, at about the same time at which cortical Ab concentrations start to become elevated [29, 51, 69] , and since both the cholinergic deficit and Ab accumulation are accentuated in AD, that both of these changes are prodromal events in AD. In non-demented subjects with plaques, previous reports have already indicated that indices of cortical pre-synaptic cholinergic elements are decreased relative to age-similar subjects without plaques [3, 4, 43] . The cause of both the cholinergic deficit and cortical plaque formation may be neurofibrillary degeneration of the nucleus basalis of Meynert, as this neuronal group is one of the first affected by this age-related change [6, 78] . In addition, we and others have causally linked cortical cholinergic deafferentation or dysfunction to Ab deposition in animal models, through immunotoxin lesions of the basal forebrain cholinergic neurons [5, 8] and M1 receptor knockout of amyloid precursor protein (APP) transgenic mice [21] . Other animal models do not support the competing retrograde theory of cholinergic degeneration, as it has been shown that neither cortical lesions [52] nor marked Ab deposition [30, 35, 86] necessarily result in significant losses of cortical cholinergic markers.
The results presented here are the first report of a preclinical alteration of post-synaptic function in AD. The M1 muscarinic receptor displays both a high affinity and a low affinity binding site when displacement of an antagonist by an agonist is measured. The addition of a non-hydrolyzable GTP analog such as GppNHp causes the complex to dissociate, shifting the binding towards the low-affinity site (uncoupling from the G-protein). Non-demented elderly subjects with plaques show a shift of M1 muscarinic receptor binding from high affinity to low affinity, and a decrease in the displacement of competition binding curves with GppNHp, consistent with uncoupling of M1 receptors from their G-proteins. While the loss of cortical cholinergic presynaptic terminal markers in AD has been extensively documented, much less attention has been paid to the status of postsynaptic receptors, and, possibly because of the greater complexity of the post-synaptic apparatus, there is not yet a complete picture of cholinergic postsynaptic function in the disease. Although there may be little or no change, or even a small increase in the number of M1 muscarinic receptors [64, 65, 70, 84] , multiple measures of M1 receptor signal transduction-related markers or function are reportedly decreased or impaired in AD [26, 34, 59, 80, 81, 84, 85] .
The cause of receptor uncoupling in the presence of plaques or AD is unclear. Uncoupling could result from increased concentrations of soluble Ab, as studies in animals have demonstrated that Ab exposure can lead to uncoupling of the M1 receptor [44] . Receptor uncoupling may also be secondary to loss of cholinergic presynaptic terminals, as we have observed this in rats with depleted cortical cholinergic afferents due to intracerebroventricular injection of the immunotoxin IgG 192-saporin (unpublished results). Uncoupling in these animals was prevented by treatment with a muscarinic receptor agonist. In addition, treatment of AD subjects with an acetylcholinesterase inhibitor has been reported to increase cortical uptake of 123 I quinuclidinylbenzilate (QNB), consistent with an increase in high affinity binding sites [45] . These data suggest that cholinergic therapy at the preclinical stages of AD may be beneficial by augmenting or preserving postsynaptic cholinergic function.
The early situation of the cortical cholinergic deficit in AD indicates that it could have a critical causative or accelerating effect on AD pathogenesis and thus be an important target for AD prevention therapy. There is mounting evidence, derived from both basic science and clinical studies, consistent with a disease-modifying effect for cholinergic therapy. In vitro, animal and human studies have linked M1 muscarinic receptor activation status with the metabolism of bAPP and Ab [16, 17, 21, 25, 27, 62] . The results of multiple clinical trials as well as some imaging studies are also consistent with disease modification [11, 15, 40, 46, 49, 55, 72] . Recent trials of acetylcholinesterase inhibitors in subjects with mild cognitive impairment (MCI) showed definite effects on the rate of cognitive deterioration and/or conversion to AD [49, 72] . These effects may have been underestimated as recent clinicopathological studies [41, 71, 76] have demonstrated that up to one-third to one-half of MCI cases are not pathologically AD, so that any disease-specific effects of the medication may have been diluted by the inclusion of subjects that did not have AD. In any case, as both amyloid plaque deposition and the cholinergic deficit are already likely to be well advanced even by the time mild cognitive impairment appears, primary prevention trials may be necessary to adequately test whether cholinergic therapy can slow or halt disease progression. The results shown here suggest that cholinotropic agents are a logical choice for primary prevention trials. These trials would be optimized by enhanced selection of high-risk subjects using amyloid imaging in combination with in vivo imaging of cortical cholinergic afferents. Fig. 7 Percent of binding sites in high affinity state. Percent of binding sites in the high-affinity state was determined using two-site competition curves for displacement of pirenzepine by oxotremorine-M. The groups differ significantly and all differ in pairwise comparisons with elderly non-demented subjects (p \ 0.05) with no plaques (NPL). SPL elderly non-demented subjects with sparse plaques, MPL elderly non-demented subjects with many plaques, GppNHp samples to whose samples GppNHp was added (see ''Materials and methods''). The sample sizes are as given in Fig. 5 except for the GppNHp group, which was composed of samples from all groups combined (N = 17 for NPL group; N = 10 for SPL group; N = 5 for MPL group; N = 21 for AD group)
